header
May 14, 2021

In This Issue
Governor Announces Maine Will Follow New CDC Guidance on Masks for Fully Vaccinated People
FDA Adds Adolescents Age 12 Through 15 to Pfizer-BioNTech COVID-19 Vaccine EUA
AMA Pledges in New Plan to Dismantle Causes of Health Inequities
Vaccine Ordering Open to All MIP-approved COVID Vaccine Providers Through Maine CDC
Another Busy Week for Maine Medical Association Legislative Advocacy
MMA Mary Cushman, MD Award for Humanitarian Service
Tufts Maine Track Class of 2021
UNECOM
This Week’s Top Articles from JAMA Network
SUPPORT for ME Training and Technical Assistance Initiative
Maine Community Action Partnership is Working for a Successful Vaccine Roll Out for All
A Message from Maine Responds: Volunteer Opportunity
MAINE LEGISLATURE
Maine Medical Association State Legislative Priorities Update
Next MMA Legislative Call Will Be Wednesday, May 19th
UPCOMING EVENTS
Upcoming Specialty Society Meetings
NAMI Maine June Workshop: Suicide Assessment & Management for Clinical Staff
AAP EQIPP Course: Immunizations - Strategies for Success (for RURAL Health Providers)
New Maine AAP Educational Webinar Series
SBIRT/EFFECTIVE CONVERSATION TRAINING - Saturday, May 15th, 8:30am
2021 PREVENTION PROFESSIONALS CONFERENCE: Striving for Inclusive Prevention During the Pandemic and Beyond May 18-19, 2021
Medical Society Consortium on Climate and Health Annual Meeting May 21-25
Maine Opioid Prescribing Legal Update May 25, 2021
HEALTHCARE EMPLOYMENT OPPORTUNITIES
Medical Director / Physician
Finance Director for Islands Community Medical Services

 
Search Back Issues



 

 

 


Follow Us:
FDA Adds Adolescents Age 12 Through 15 to Pfizer-BioNTech COVID-19 Vaccine EUA

14 year-old Mainer, Henry Fisher received his first shot earlier this week from Mid Coast Hospital

On Monday, the U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to include adolescents 12 through 15 years of age. The FDA amended the EUA originally issued on Dec. 11, 2020 for administration in individuals 16 years of age and older. 

· Read full announcement here 

· Virtual Press Conference: COVID-19 Vaccine for Adolescents 

· New American Academy of Pediatrics Policy on COVID-19 Vaccines for Children 

· AMA: Pfizer’s COVID-19 vaccine OK’d for ages 12–15: What doctors must know 

The FDA has updated the Fact Sheets for Healthcare Providers Administering the Vaccine (Vaccination Providers) and for Recipients and Caregivers with information to reflect the use of the vaccine in the adolescent population, including the benefits and risks of the Pfizer-BioNTech COVID-19 Vaccine. 

The available safety data to support the EUA in adolescents down to 12 years of age, include 2,260 participants ages 12 through 15 years old enrolled in an ongoing randomized, placebo-controlled clinical trial in the United States. 

The most commonly reported side effects in the adolescent clinical trial participants, which typically lasted 1-3 days, were pain at the injection site, tiredness, headache, chills, muscle pain, fever and joint pain. With the exception of pain at the injection site, more adolescents reported these side effects after the second dose than after the first dose, so it is important for vaccination providers and recipients to expect that there may be some side effects after either dose, but even more so after the second dose. 

Emergency Use Authorization for Vaccines Explained

 

< Previous Article | Next Article >

[ return to top ]

To ensure delivery of Maine Medicine Weekly Update,
please add 'info@mainemed.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm


Unsubscribe here

For more information or to contact us directly, please visit www.mainemed.com | ©